U.S. President Donald Trump on Tuesday signed an executive order that aims to delay Medicare negotiations for a broad category of prescription drugs, handing the deep-pocketed pharmaceutical industry a major win as it lobbies aggressively against efforts to rein in its pricing power.
"Further delaying Medicare drug price negotiation would lead to higher prices for patients and taxpayers, not lower ones," said Steve Knievel, a drug policy advocate at Public Citizen.
